SEOUL -- Chinese companies are increasingly shipping U.S.-bound goods to South Korea and then fraudulently exporting them as South Korean products in order to avoid steep American tariffs on ...

On Tuesday, following the Pacers' 123-115 Game 2 victory over the Milwaukee Bucks, Carlisle reacted to an anonymous NBA player's poll labeling Tyrese Haliburton as the "most overrated." ...

USAA settles class-action lawsuit over 2021 data breach affecting 22,600 members. Deadline for filing claims has passed. Victims have been notified. Settlement checks expected after final court ...

The PRELUDE trial is assessing oncological outcomes with neoadjuvant 177Lu-PSMA-617 in high-risk, localized prostate cancer. 177 Lu-PSMA-617 (Pluvicto) was approved by the FDA in March 2022 for ...

Journal of Nuclear Medicine April 2025, jnumed.124.269431; DOI: https://doi.org/10.2967/jnumed.124.269431 ...

which if it reaches the market would be a rival to Novartis’ Lutathera (lutetium [177Lu] oxodotreotide), approved as a second-line therapy for GEP-NETs and due to be filed shortly as first-line ...

"The goal of the PRECISION study is to ensure that treatment with 3 radiation doses does not lead to greater side effects than those observed in the PACE-B study," says Professor Duncan B. McLaren, ...

Pedro C. Barata, MD, MSc, associate professor of medicine at Case Western University and director of the Clinical Genitourinary Medical Oncology Research Program at University Hospitals Seidman Cancer ...

远大医药方面表示，目前远大医药围绕肿瘤诊疗一体化的治疗理念，深度布局放射性药物研发，公司核药抗肿瘤诊疗板块目前在研发注册阶段已储备13款创新产品，涵盖68Ga、177Lu、131I、90Y、89Zr在内的5种放射性核素，覆盖了肝癌、前列腺癌、肾癌、脑癌等在内的7 ...

Another is Lutetium-177, used in 177Lu-PSMA-617, which precisely targets prostate cancer. This is where radiopharmaceuticals intersect with theranostics – a field that combines diagnosis and ...